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ABSTRACT
Objective An unmet need exists for a non- invasive 
biomarker assay to aid gastric cancer diagnosis. We 
aimed to develop a serum microRNA (miRNA) panel for 
identifying patients with all stages of gastric cancer from 
a high- risk population.
Design We conducted a three- phase, multicentre 
study comprising 5248 subjects from Singapore and 
Korea. Biomarker discovery and verification phases were 
done through comprehensive serum miRNA profiling 
and multivariant analysis of 578 miRNA candidates in 
retrospective cohorts of 682 subjects. A clinical assay 
was developed and validated in a prospective cohort of 
4566 symptomatic subjects who underwent endoscopy. 
Assay performance was confirmed with histological 
diagnosis and compared with Helicobacter pylori (HP) 
serology, serum pepsinogens (PGs), ’ABC’ method, 
carcinoembryonic antigen (CEA) and cancer antigen 
19–9 (CA19-9). Cost- effectiveness was analysed using a 
Markov decision model.
Results We developed a clinical assay for detection 
of gastric cancer based on a 12- miRNA biomarker 
panel. The 12- miRNA panel had area under the curve 
(AUC)=0.93 (95% CI 0.90 to 0.95) and AUC=0.92 
(95% CI 0.88 to 0.96) in the discovery and verification 
cohorts, respectively. In the prospective study, overall 
sensitivity was 87.0% (95% CI 79.4% to 92.5%) at 
specificity of 68.4% (95% CI 67.0% to 69.8%). AUC 
was 0.848 (95% CI 0.81 to 0.88), higher than HP 
serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), 
ABC method (0.647), CEA (0.576) and CA19-9 (0.595). 
The number needed to screen is 489 annually. It is cost- 
effective for mass screening relative to current practice 
(incremental cost- effectiveness ratio=US$44 531/
quality- of- life year).
Conclusion We developed and validated a serum 
12- miRNA biomarker assay, which may be a cost- 
effective risk assessment for gastric cancer.
Trial registration number This study is registered 
with  ClinicalTrials. gov (Registration number: 
NCT04329299).
INTRODUCTION
Gastric cancer (GC) is the fifth most common cancer 
and the third- leading cause of cancer deaths world-
wide.1 GC mortality is high due to late presenta-
tion.2 In high- incidence countries, such as Japan 
and Korea, mass screening for GC is practiced 
using photofluorography or, more recently, endos-
copy. In these settings, over 50% of GC patients are 
diagnosed at early stages and their survival is excel-
lent.3 4 However, in most countries, mass screening 
is neither feasible nor cost- effective because such 
screening methods are costly and invasive, with 
Significance of this study
What is already known on this subject?
 ► Circulating microRNAs (miRNAs) are promising 
biomarkers for detection of gastric cancer (GC) 
but previous studies were limited by small 
cohort sizes and the use of research grade 
assays.
What are the new findings?
 ► This is the most extensive evaluation of 
circulating miRNAs as biomarkers for GC 
detection to date, as measured by both cohort 
size and technical stringency. A clinical assay 
based on a panel of 12- miRNA biomarkers was 
developed, manufactured to clinical standards, 
and prospectively validated in a multicentre 
cohort of over 5000 subjects. The assay was 
more accurate than any existing blood- based 
diagnostic biomarkers for GC and it could 
reduce the number of unnecessary upper 
endoscopy. It was also cost- effective as a 
screening test for GC.
How might it impact on clinical practice in the 
foreseeable future?
 ► The serum miRNA biomarker panel can be 
used as a risk assessment tool for GC before 
endoscopy. It has the potential to be a cost- 
effective mass screening tool for GC.
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poor compliance.4 There is an unmet need for a less invasive and 
cost- effective GC screening test.
Currently available gastrointestinal tumour markers, including 
carcinoembryonic antigen (CEA) and cancer antigen 19–9 
(CA19-9) are inadequate for GC screening due to their poor 
sensitivities, especially for early- stage GC.5 Recently, the ABC 
method, a combination of age, serum anti- Helicobacter pylori 
(HP) IgG antibody (serology) and pepsinogen (PG) 1 and 2 
levels, have shown some promise as a blood test for GC risk 
stratification in Japan but its clinical performance has varied 
among different populations.4 6 7
MicroRNAs (miRNAs or miRs) are small non- coding RNAs 
that regulate gene expression post- transcriptionally.8 Aberrant 
expression of miRNAs has been implicated in the pathogenesis 
of many diseases, including cancer.9 10 Cell- free miRNAs have 
been shown to circulate stably in serum and plasma,11 12 and 
dysregulation of their expressions correlate with cancer onset 
and progression, making them attractive biomarker candi-
dates.12 13 However, sensitive and robust detection of these 
circulating miRNA from clinical samples is challenging due to 
their small size and low abundance.14 To overcome these chal-
lenges, we developed a proprietary miRNA RT- qPCR assay plat-
form with greater sensitivity and reproducibility in detecting 
circulating miRNAs using small- volume clinical samples.15
The primary aim of this study is to develop a serum panel of 
miRNA as a non- invasive test that can detect GC of all stages 
and validate its performance in a large prospective cohort. The 
secondary aim is to evaluate its cost- effectiveness as a mass 
screening tool for GC.
METHODS
Study design and patient cohorts
We conducted a three- phase, multicentre study to discover and vali-
date a panel of serum miRNA biomarkers for GC. In the discovery 
phase, we measured the expression of 578 circulating miRNAs in a 
case–control cohort of 472 Singaporean Chinese subjects, including 
236 cancer and 236 matched control subjects, to identify candi-
date biomarker miRNAs as well as candidate multi- miRNA panels. 
A total of 236 patients with cancer were from the Gastric Cancer 
Biomarker Discovery Study (GASCAD), which recruited newly 
diagnosed GC patients. Blood was collected prior to any cancer 
treatment. Matched control subjects were enrolled through the 
Gastric Epidemiology and Molecular Genetics Project (GCEP), 
a prospective cohort study that aimed to identify GC risk factors 
in the Singapore Chinese population with age 50 or above and 
to develop a screening algorithm.16 All control subjects received 
surveillance endoscopy with standardised biopsy protocol at 
regular intervals and were confirmed to have no GC or high- grade 
dysplasia based on endoscopy and histological examination. GC 
patients and controls were matched in ethnicity (Chinese), sex and 
age (±10 years).
In the verification phase, we confirmed the dysregulation of 
candidate biomarkers and identified a 12- miR panel in another 
case–control cohort of 210 Singaporean and Korean subjects, 
including 94 cancers and 116 matched controls. Blinded 
biomarker verification was performed with sera specimen 
from cancer and control subjects recruited from Singapore and 
Korea. The Singaporean sample set included 20 additional GC 
patients and 69 matched controls from GASCAD and GCEP 
cohorts respectively. The Korean sample set included 74 GC 
patients recruited at Yonsei Cancer Center and 47 controls who 
were healthy blood donors from Songdang Institute for Cancer 
Research.
After the verification phase, a clinical grade multivariate index 
assay based on the 12- miR panel was formulated. Finally, the 
performance of this 12- miR panel was validated in a prospec-
tive cohort of 4566 Singaporean subjects who underwent upper 
endoscopy for their gastrointestinal symptoms. Patients eligible 
for inclusions were consecutive adults, between the ages of 40 
and 90 years, who were scheduled to undergo gastroscopy based 
on standard clinical indications at National University Hospital 
and Tan Tock Seng Hospital in Singapore from 2013 to 2016. 
A total of 5282 subjects were recruited. Subjects with a history 
of total or partial gastrectomy were excluded. The presence 
and absence of GC and high- grade dysplasia were confirmed 
by endoscopy and histological examinations. Written informed 
consent was obtained from all participants.
Blood collection and serum processing
Fasting blood samples (20 mL) were withdrawn from each subject 
via venipuncture and collected in two plain serum tubes (BD 
vacutainer plus plastic serum tube). The serum tubes were centri-
fuged at 3000 rpm at 20°C for 10 min. Centrifugation and serum 
collection was done within 4 hours of blood collection. Serum spec-
imen were aliquoted and stored immediately at −80°C.
MiRNA quantification in discovery and verification phases
The absolute expression (copy numbers) of 578 candidate 
miRNAs were quantified in each patient and control biospec-
imen using miRNA- specific RT- qPCR assays (MiRXES, Singa-
pore) via a highly controlled workflow illustrated in online 
supplemental figure S1. The analytical specificity, reproduc-
ibility and sensitivity of the assay and workflow (online supple-
mental methods) are shown in online supplemental figure S2. 
Total RNA from 200 µL of patient and control serum specimen 
was isolated using miRNeasy serum/plasma miRNA isolation kit 
(Qiagen, Germany). Synthetic miRNA controls were added to 
samples before RNA isolation, and RT- qPCR to monitor and 
normalise technical variations throughout the entire workflow 
(online supplemental methods). Absolute expression of each 
miRNA was determined in each patient serum sample and 
normalised across samples using endogenous reference miRNAs 
(online supplemental methods).
12-miR assay in validation phase
A central biorepository received all serum specimens. The 12- miR 
qPCR assay was developed and manufactured in accordance 
with the ISO13485 medical devices quality management systems 
(MIRXES, Singapore). Laboratory testing (online supplemental 
methods) was performed in CAP/ISO- certified laboratories 
without knowledge of the results of endoscopic and histopatho-
logical findings. Eleven GC related miRNAs (miR-140, miR-183, 
miR- 30e, miR- 103a, miR-126, miR-93, miR-142, miR-21, miR- 
29c, miR-424 and miR- 181a) were measured together with a 
reference miRNA (miR-340) (online supplemental methods). All 
qPCR measurements were performed in duplicates. The assay 
generated a numerical GC risk score for each sample using the 
GASTROSmart Software (MIRXES, Singapore) (online supple-
mental methods). Using the 12- miRNA panel, a cancer predic-
tion score was generated based on the most optimal sensitivity 
and specificity combination. The risk score was calculated using 
a linear regression model of the measured expression levels of 
the 12 miRNAs in the panel. A score of 40 or more was defined 
as a positive test result.
Other blood-based GC marker assays
Serum biomarkers CEA, CA19-9, anti- HP IgG, PG 1 and PG 
2 were also measured. CEA, CA19-9, PG 1/2 ratio, PG index 
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(combining a PG 1 level cut- off and PG 1/2 ratio), and the so- called 
‘ABC method’ by combining HP serology and PG 1/2 ratio have 
previously been proposed as biomarkers for GC screening.4 6 7 17 
Serum specimens were qualitatively assayed for HP antibodies 
with the MP Diagnostics HELICO BLOT 2.1 Western blot kit 
assay (MP BIOMEDICALS Asia Pacific). PG I and II levels were 
determined with latex agglutination turbidimetric immunoassay 
kit (LZ Test ‘Eiken’ PG I and II, Tokyo, Japan). Access CEA and 
CA19-9 chemiluminescent sandwich immunoassays (Beckman 
Coulter, USA) were run on the UniCel DxI 800 immunoassay 
system (Beckman Coulter, USA). All assays were performed 
without knowledge of the clinical findings.
Health economic analysis
The overall costs and health benefits of conducting mass screening 
using the validated miRNA panel relative to current practice of 
no- screening were estimated for a hypothetical cohort, with 
assumed health seeking behaviours, disease incidence/progres-
sion and associated patient quality- of- life years (QALY) repre-
sentative of a high- risk population in Singapore (Chinese males 
of 50–75 years old). We assumed that miRNA test- positive 
subjects would go on to have a confirmatory endoscopy while 
test- negative subjects would be followed up in 3 years. Further 
modelling and parameter uncertainties were addressed using 
sensitivity analysis. Details of this analysis are provided in online 
supplemental methods.
Statistical analysis
During the discovery phrase, significantly regulated miRNAs 
were identified using Student’s t- tests with a false discovery rate 
(FDR) correction.18 The receiver operating characteristic curve 
was used to present the performance of individual miRNA or 
multivariant biomarker panels. A sequential forward floating 
search (SFFS) algorithm19 was used to optimise the miRNA 
biomarker panel, with area under the curve (AUC) values as the 
performance indicator. Multivariate analysis was carried out to 
construct multi- miR panels with associated algorithms for clas-
sifying cancers and controls (online supplemental methods). 
Multivariate Cox regression analysis of the 12- miR panel and 
clinical covariates was carried out.
For the prospective validation study, the sample size was calcu-
lated based on an expected 2% prevalence of GC in a high- risk 
symptomatic population and a point estimate of 85% sensitivity 
based on discovery and verification data. We planned to recruit 
about 5000 participants to achieve margins of sampling error of 
approximately 5 percentage points for sensitivity.
The study was reported according to Standards for Reporting 
of Diagnostic Accuracy Studies 2015 guidelines.20
RESULTS
Identification of GC associated serum miRNA biomarkers
GC- associated serum miRNA biomarkers were identified 
through retrospective analysis of 472 prospectively collected 
specimens from GC patients and controls matched by age, sex 
and ethnicity. Clinicopathological characteristics of the discovery 
cohort are shown in table 1. The cohort was enriched for early 
stage GC patients (30.1% stage 1 and 15.3% stage 2) to ensure 
that it was sufficiently powered to identify biomarkers associ-
ated with early stage GC. We systematically evaluated an a priori 
list of 578 circulating miRNAs using a highly controlled and 
analytically validated RT- qPCR workflow. Prior to biomarker 
discovery, the analytical sensitivity, specificity and reproduc-
ibility of the miRNA assay and workflow were validated using a 
combination of synthetic miRNA templates. These assays demon-
strated strong discrimination against highly homologous miRNA 
sequences (online supplemental figure S2A), high concordance 
in detecting circulating miRNAs in both control and cancer sera 
(online supplemental figure S2B), and good dynamic range in 
amplifying and detecting miRNAs with distinct sequences and 
varying AT content (online supplemental figure S2C).
Of 578 serum miRNAs quantified, 191 miRNAs were detected 
in more than 90% of the subjects (expression levels ≥500 copies/
mL of serum) (online supplemental table S1); 75 of the 191 
miRNAs were differentially expressed between cancer patients 
and matched controls (FDR corrected p<0.01) (online supple-
mental table S2). Of the 75 dysregulated miRNAs, 68 were novel 
discoveries; 51 were upregulated and 24 downregulated (online 
supplemental tables S2 and S3). An expression heatmap of the 
dysregulated miRNAs showed the majority of GC subjects clus-
tered closely (figure 1A). Many of these miRNAs were positively 
correlated (Pearson correlation coefficient (r) >0.6) (figure 1B), 
suggesting potential co- regulation in miRNA expression. Among 
the dysregulated miRNAs, miR-142–5 p (upregulated) and 
miR- 99b- 5p (downregulated) exhibited the highest AUC, at 
0.71 and 0.67, respectively (online supplemental figure S3A). 
Seven miRNAs were found to be differentially expressed (FDR 
corrected p<0.05) in the three histological subtypes (diffuse, 
intestinal and mixed) of GC (online supplemental figure S4). 
Thirty- six miRNAs were differentially regulated at various stages 
of GC (FDR corrected p<0.01) (online supplemental figure S3B 
and table S4).
Table 1 Discovery cohort clinicopathological characteristics
Singaporean






Gender Male 150 (63.3%) 148 (62.7%)
Female 87 (36.7%) 88 (37.3%)
Age 61.2±8.4 (SD) 68.0±10.9 (SD)
Ethnicity Chinese (%) 236 (100%) 236 (100%)
Stages (AJCC 2010) Stage 0 (%) – –
Stage 1 (%) – 71 (30.1%)
Stage 2 (%) – 36 (15.3%)
Stage 3 (%) – 54 (22.9%)
Stage 4 (%) – 75 (31.8%)
Unknown (%) – –
Histological subtype Intestinal – 134 (56.8%)
Diffuse – 70 (29.7%)
Mixed – 32 (13.6%)
Unknown – –
Gastritis No 7 (3.0%) 36 (15.3%)
Yes 230 (97.0%) 200 (84.7%)
Unknown – –
Intestinal metaplasia No 116 (48.9%) 75 (31.8%)
Yes 121 (51.1%) 161 (68.2%)
Unknown – –
Atrophy No 133 (56.1%) 215 (91.1%)
Yes 104 (43.9%) 21 (8.9%)
Unknown – –
Helicobacter pylori No 105 (44.3%) 50 (21.2%)
Yes 132 (55.7%) 186 (78.8%)
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Next, we developed and tested multi- miRNA biomarker 
panels with high AUC in distinguishing cancer from controls 
using cross- validation. The discovery cohort was partitioned 
into equally sized training and test sets matched for cancer stage, 
subtype, age, gender and ethnicity.21 We derived multi- miRNA 
biomarker panels in training set using SFFS and SVM and 
tested the panel performance in the test set. The composition 
of the miRNA panels included a combination of miRNAs that 
were individually significant and non- significant between GC 
and matched controls. An improvement in AUC was observed 
when number of miRNAs in the panel increased but plateaued 
at 12- miRNAs. The median AUC values for a 12- miRNA panel 
were close to 0.90 in the test set, with a spread between the 
25th and 75th percentile of <0.05 (figure 1C). Incorporating 
more miRNAs into the panel did not significantly improve AUC. 
Multivariate Cox regression analysis showed that the 12- miRNA 
biomarker panel was independent of clinical covariates in 
detecting GC (online supplemental table S5).
Verification of miRNA biomarker panel
We verified the performance of individual miRNAs and the 
12- miR panel in two independent retrospective case–control 
cohorts of 89 subjects from Singapore and 121 subjects from 
Korea (table 2). We observed good correlations in individual 
miRNA expression fold- changes between the discovery cohort 
and each of the two verification cohorts (figure 2A).
Similarly, the 12- miR panel identified through the discovery 
cohort showed consistency in the verification cohorts. The panel 
was able to discriminate GC from matched controls with AUC 0.93 
Figure 1 Identification of candidate miRNA biomarkers and multi- miRNA biomarker panels for gastric cancer detection. (A) Heat- map showing 
expression levels of serum miRNAs that were differentially regulated in gastric cancer. The full list can be found in in online supplemental table 
S2; absolute miRNA expression levels (copy/mL) of miRNAs were presented in log2 scale and standardised to zero mean. Hierarchical clustering 
was carried out for both dimensions (miRNAs and samples) based on Euclidean distance. (B) Correlation in expression levels between differentially 
regulated miRNAs. Pearson’s linear correlation coefficients were calculated between all 75 miRNAs that were identified to be differentially regulated 
in gastric cancer (online supplemental table S2). (C) Gastric cancer detection accuracy of multi- miRNA biomarker panels with 3–10 miRNAs as 
determined by mean area under ROC curve (AUC). Biomarker panels were tested in the discovery cohort. Two hundred iterations of a cross- validation 
process were carried out by dividing the Discovery cohort into two data sets: training and testing. Error bars indicate SD. Statistical significance of 
difference in AUC was determined using Student’s t- test (one sided, **p<0.01; ***p<0.001). AUC, area under the curve; miRNA, micro- RNA.
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(95% CI 0.90 to 0.95) in discovery cohort and 0.92 (95% CI 0.88 
to 0.96) in the verification cohort. When comparing early- stage GC 
(stages 1–2) from matched controls, the panel achieved AUC 0.90 
(95% CI 0.85 to 0.94) in the discovery cohort and 0.91 (95% CI 
0.85 to 0.96) in the verification cohort (figure 2B). The verified 
12- miR panel (miR-140, miR-183, miR- 30e, miR- 103a, miR-126, 
miR-93, miR-142, miR-21, miR- 29c, miR-424, miR- 181a and 
miR-340) was thus finalised and developed into a clinical assay in 
accordance with the ISO13485 medical devices quality manage-
ment system for prospective validation.
Prospective validation of the 12-miR assay
Study population
The 12- miR assay, with a prespecified prediction algorithm, was 
validated in a large prospective validation cohort of Singaporean 
patients (figure 3). The clinicopathological characteristics are 
shown in table 3. A total of 5282 participants underwent endos-
copy, and had serum collected for testing with the 12- miR assay 
and other serum- based biomarker tests that have been suggested 
for GC detection (HP serology, PG 1/2 ratio, PG index, ABC 
method, CEA and CA19-9). 597 subjects were excluded from 
miRNA analysis due to sample quality issues. Of the remaining 
4685 samples assayed, 4570 (97.5%) yielded valid test results. 
The remaining samples did not yield valid results due to invalid 
expression ranges or were excluded from data analysis due to 
incomplete clinical information. Altogether, 4566 participants 
had results that could be fully analysed for the 12- miR assay, 
HP serology, CEA and CA19-9 tests. A total of 133 samples 
were excluded from PG 1/2 analysis because patients had renal 
failure which affects PG levels. A total of 4433 patients had 
results for the PG tests which could be analysed. A total of 115 
biopsy- proven GC was found by endoscopy (prevalence, 2.5%). 
Another 10 participants were found to have gastric high- grade 
dysplasia.
Assay performance
The 12- miR distinguished GC from matched normal controls 
with AUC 0.848 (95% CI 0.809 to 0.880) (figure 4A). This GC 
detection accuracy was higher than HP serology (AUC 0.635, 
95% CI 0.594 to 0.668), PG 1/2 ratio (AUC 0.641, 95% CI 
0.567 to 0.705), PG index (AUC 0.576, 95% CI 0.540 to 0.626), 
ABC method (AUC 0.647, 95% CI 0.60 to 0.681), CEA (AUC 
0.576, 95% CI 0.512 to 0.638) or CA19-9 (AUC 0.595, 95% CI 
0.535 to 0.656) (figure 4A,B).
The 12- miR assay identified 100 of 115 GC detected by 
endoscopy, for an overall sensitivity of 87.0% (95% CI 79.4% to 
92.5%) at a specificity of 68.4% (95% CI 67.0% to 69.8%). The 
12- miR assay achieved the highest sensitivity among the serum- 
based biomarker tests (figure 4C). PG, CEA and CA19-9 tests 
had higher than 90% specificity but lower than 30% sensitivity 
for GC detection. GC detection accuracy with the 12- miR assay 
can be improved by including patient’s age, HP serology and PG 
1/2 ratio (figure 4D). Using this combination, AUC was improved 
to 0.884, with specificity of 69.4% at sensitivity of 87.0%. GC 
detection sensitivity of the 12- miR did not vary significantly by 
Table 2 Verification cohort clinicopathological characteristics
Verification phase
Singaporean Korean










Gender Male 32 (46.4%) 14 (70.0%) 35 (74.5%) 44 (59.5%)
Female 37 (53.6%) 6 (30.0%) 12 (25.5%) 30 (40.5%)
Age 63.3±8.4 (SD) 74.8±9.5 (SD) 26.4±2.7 (SD) 59.1±10.6 (SD)
Ethnicity Chinese (%) 69 (100%) 20 (100%) – –
Korean (%) – – 47 (100%) 74 (100%)
Stages (AJCC 2010) Stage 0 (%) – – – –
Stage 1 (%) – 10 (50.0%) – 17 (23.0%)
Stage 2 (%) – 3 (15.0%) – 21 (28.4%)
Stage 3 (%) – 6 (30.0%) – 17 (23.0%)
Stage 4 (%) – 1 (5.0%) – 19 (25.7%)
Unknown (%) – – – –
Histological subtype Intestinal – – – 35 (47.3%)
Diffuse – – – 31 (41.9%)
Mixed – – – 0 (0.0%)
Unknown – – – 8 (10.8%)
Gastritis No 0 (0%) 0 (0%) – –
Yes 69 (100%) 12 (60%) – –
Unknown – 8 (40%) – –
Intestinal metaplasia No 17 (24.6%) 0 (0.0%) – –
Yes 52 (75.4%) 10 (50.0%) – –
Unknown – 10 (50.0%) – –
Atrophy No 32 (46.4%) 0 (0.0%) – –
Yes 37 (53.6%) 1 (5.0%) – –
Unknown – 19 (95.0%) – –
H Pylori No 18 (26.1%) 2 (10.0%) – –
Yes 51 (73.9%) 18 (90.0%) – –
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cancer stage, gender and ethnicity but tends to be higher in older 
patients, larger tumour and intestinal- type GCs (figure 5).
To detect 115 GC cases in a symptomatic population, 4566 
gastroscopies were carried out. Therefore, 40 gastroscopies will 
be required to detect one case of GC if no biomarker test were 
used. In comparison, only 15 endoscopies will be required if the 
12- miR assay result was used to select patients for endoscopy 
in the same population. The positive predictive value (PPV) of 
using the 12- miR assay is 6.7% while the negative predictive 
value (NPV) is 99.5%. The assay had minimal cross- reactivity 
with other common cancers including those of the gastrointes-
tinal tract (online supplemental table S6 and figure S6).
Health economic analysis
Using an assumption of compliance reflective of the existing 
screening programmes in Asia (45%), the number needed to 
screen (NNS) with the 12- miR assay in order to detect one case 
of GC was calculated to be 489 annually. Mass screening with 
the 12- miR assay can increase early- stage GC detection rate to 40 
per 100 cancers identified, compared with 30 per 100 in current 
practice (table 4). Overall, mass screening using the 12- miR 
assay added costs of USD 175 per subject. The ratio of addi-
tional cost to additional health gains, or the incremental cost- 
effectiveness ratio is USD44 531/QALY, which is cost- effective in 
the local context, compared with the WHO- CHOICE threshold 
of approximately USD50 000/QALY (table 5). We anticipate that 
actual compliance for mass screening is likely to be significantly 
higher for a non- invasive test compared with endoscopy.
DISCUSSION
In recent years, miRNAs have been investigated as promising 
GC biomarkers because many solid tumours exhibit dysreg-
ulation of miRNA expression.13 Patients with cancer exhibit 
aberrant expression of circulating miRNAs in biofluids such 
as blood.22 23 However, change in miRNA expression in blood 
is less readily detected than changes in tissue due to multiple 
tissue sources for circulating miRNA and multiple physiolog-
ical or pathological conditions affecting miRNA quantities. It is 
also technically challenging to detect miRNAs because of their 
small size. Previous studies exploring circulating miRNAs as GC 
biomarkers have shown promising proof- of- concept results but 
remain largely inconclusive, possibly due to small cohort sizes 
(n=6 to 570),24–26 and the use of research grade assays.27
Figure 2 Verification of gastric cancer miRNA biomarkers and multi- 
miRNA biomarker panel detection accuracy in independent cohorts. 
(A) Correlation in expression level fold changes (cancer over control) 
of verified miRNA biomarkers between the discovery cohort and 
verification cohorts. (B) Receiver operating characteristics (ROC) curves 
for the 12- miRNA biomarker panel in detecting all gastric cancers (A) 
and early stage (stage 1–2) cancers (B). Area under the ROC curve 
(AUC) used to determine gastric cancer detection accuracy. Maximum 
classification accuracy is determined to occur at the point indicated by 
the red box. The sensitivity and specificity at this point is shown. miRNA, 
micro- RNA.
Figure 3 Prospective validation of 12- miR biomarker assay for 
detection of gastric cancer. Flow chart of prospective validation 
study design prepared in accordance with Standards for Reporting of 
Diagnostic Accuracy Studies guidelines. miR, micro RNA, NC, negative 
control; QR, quantitative reference.
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To the best of our knowledge, this is the most extensive eval-
uation of circulating miRNAs as biomarkers for GC detection 
as measured by both cohort size and technical stringency. We 
quantified the absolute expression of 578 serum miRNAs in 
682 cancer patients and control subjects using a comprehen-
sive biomarker detection platform that incorporated important 
advances that were designed to overcome the biological and 
technical challenges inherent in detecting circulating miRNA. 
Sixty- eight novel serum miRNAs associated with GC were 
discovered. Subsequently, we used multivariant data analysis to 
develop a 12- miR assay that discriminated between GC patients 
and matched high- risk controls with high accuracy (AUC >0.93). 
A clinical grade 12- miR assay was then manufactured in accor-
dance with the ISO13485 medical devices quality management 
systems and validated in a prospective cohort of 4566 patients. 
Depending on cut- off used, detection sensitivity reached 87% 
while specificity was as high as 93.9%. The assay could detect 
GC with high sensitivity across all age groups, genders, ethnic-
ities and tumour stages. The serum 12- miR assay performed 
significantly better than any of the conventional blood- based 
biomarker tests. Its performance can be further enhanced by 
combining with age and HP serology to achieve an AUC of 
0.884. Furthermore, we demonstrated the clinical specificity of 
the 12- miR assay against seven other prevalent cancers, including 
lung, breast, colorectal, liver, oesophageal, prostate and bladder 
cancer. We used a multivariate panel, instead of solitary miRNA 
biomarkers, to overcome low detection accuracy attributed to 
tumour heterogeneity.12
In the symptomatic study population, the 12- miR assay has 
a NNS to detect one cancer of 15, comparing favourably with 
NNS of 40 with unselected gastroscopy in the same population. 
While it is not the intent of the 12- miR assay to replace endo-
scopic evaluation, we believe this assay provides a useful option 
for symptomatic patients who might not be keen on initial endo-
scopic screening. The 12- miR assay is also a potential tool for 
mass screening. In this scenario, NNS was 489 annually which 
compares favourably with prostate- specific antigen, a common 
serum- based screening test for prostate cancer.28 If used for mass 
screening, the 12- miR assay is also capable of detecting more 
early- stage GCs than current practice. Furthermore, a blood- 
based test is expected to have better population compliance 
compared with a scope- based evaluation. In countries with high 
prevalence of GC, and with endoscopic screening programmes, 
such as South Korea, the 12- miR assay can enhance overall 
compliance among the population subset who decline endos-
copy. In countries with intermediate prevalence of GC and no 
current screening programmes, such as Singapore, the 12- miR 
assay can be implemented as a screening test with endoscopic 
examinations for those with positive 12- miR assay results.
There are limitations of this assay. First, the 12- miR panel 
had high sensitivity but moderate specificity. We chose a risk 
score cut- off giving high sensitivity by design to minimise false 
Table 3 Prospective validation cohort clinicopathological 
characteristics
Singaporean
Validation phase Prospective cohort
Subjects cohort size
Control subjects Patients with cancer
n=4441 n=125
Gender Male 2346 (52.83%) 76 (60.80%)
Female 2095 (47.17%) 49 (39.20%)
Age 57.17±10.48 (SD) 56.90±10.31 (SD)
Ethnicity Chinese (%) 3394 (76.42%) 96 (76.80%)
Malay (%) 325 (7.32%) 7 (5.60%)
Indian (%) 369 (8.31%) 9 (7.20%)
Others (%) 353 (7.95%) 13 (10.40%)
Stages (AJCC 2010) Stage 0 (%) – 10 (8.00%)
Stage 1 (%) – 16 (12.80%)
Stage 2 (%) – 20 (16.00%)
Stage 3 (%) – 31 (24.80%)
Stage 4 (%) – 38 (30.40%)
Unknown (%) – 10 (8.00%)
Histological subtype Intestinal – 39 (31.2%)
Diffuse – 30 (24%)
Mixed – 13 (10.4%)
Unknown – 43 (34.4%)
Intestinal metaplasia No 1936 (43.6%) 29 (23.2%)
Yes 609 (13.7%) 55 (44%)
Unknown 1896 (42.7%) 41 (32.8%)
Atrophy No 2505 (56.4%) 42 (33.6%)
Yes 37 (0.833%) 5 (4%)
Unknown 1899 (42.8%) 78 (62.4%)
Helicobacter pylori No 2015 (45.37%) 21 (16.80%)
Yes 2426 (54.63%) 104 (83.20%)
AJCC, American Joint Committee on Cancer.
Figure 4 Gastric cancer detection accuracy of 5- miR biomarker assay 
compared with other serum- based biomarker tests. (A) ROC curves for 
12- miR assay, PG 1/2 ratio, HP serology, CEA, and CA19-9 for detection 
of gastric cancer. (B) AUC for 12- miR biomarker assay compared with 
HP serology, PG 1/2 ratio, PG index, ABC method, CEA, and CA19-9 
tests. Bars show 95% CI (C) Overall sensitivity and associated specificity 
of GC detection using the 12- miR assay (both high sensitivity and 
high specificity cut- offs), HP serology, PG 1/2 ratio, PG index, ABC 
method, CEA, and CA19-9 tests. (D) Combinations of biomarker tests 
with optimal AUC for detecting gastric cancer. AUC, area under the 
curve; CA19, cancer antigen 19; CEA, carcinoembryonic antigen; HP, 
Helicobactor pylori; miR, micro- RNA; PG, pepsinogen.
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negatives since this blood test served as a prescreening test for 
GC. Patients with positive test results will undergo endoscopy 
to confirm the diagnosis. Thus, this blood assay may reduce the 
reliance on endoscopy. Any test will have false negatives and it 
does not supplant clinical review and consideration for endos-
copy if symptoms persist. It is not the intent of the 12- miR assay 
to replace endoscopic evaluation, we believe this assay provides 
an option for patients who might not be keen on initial endo-
scopic screening, and adds to the current cancer evaluation 
tool armamentarium, just as the stool DNA test is an option for 
colon cancer screening. Second, most controls in this study were 
patients with gastrointestinal symptoms referred to hospital 
clinics. Care should be taken when applying these findings to 
the general population. This 12- miR assay has obtained regu-
latory approval in Singapore and post- market surveillance data 
being gathered will clarify the PPV and NPV in different clinical 
settings, including in the general population. To date, the NPV in 
the general population is encouraging (data not shown). Further-
more, the study population is entirely Asian. Future studies in 
other populations should be considered. Finally, the roles that 
these GC- associated circulating miRNAs play in GC develop-
ment and progression have not been defined through func-
tional studies. Some of these miRNAs were shown to promote 
cancer metastasis and modulate tumour immune environment, 
additional mechanistic studies in cell and animal models are 
required.29 30
In conclusion, we have developed and validated a serum 
miRNA biomarker panel assay as a risk assessment tool for 
detecting GC. This assay is a useful adjunct in the armamen-
tarium for cancer screening and has the potential to be a cost- 
effective mass screening tool for GC.
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3- yearly follow- ups
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